CELLULAR BIOMEDICINE GROUP, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • March 23rd, 2016 • Cellular Biomedicine Group, Inc. • Biological products, (no disgnostic substances) • New York
Cellular Biomedicine Group, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
CELLULAR BIOMEDICINE GROUP, INC. and , as Trustee FORM OF INDENTURE Dated as of ,Indenture • March 23rd, 2016 • Cellular Biomedicine Group, Inc. • Biological products, (no disgnostic substances) • New York
PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXECUTION AND AUTHENTICATION 7 2.4. REGISTRAR AND PAYING AGENT 8 2.5. PAYING AGENT TO HOLD ASSETS IN TRUST 8 2.6. SECURITYHOLDER LISTS 9 2.7. TRANSFER AND EXCHANGE 9 2.8. REPLACEMENT SECURITIES 9 2.9. OUTSTANDING SECURITIES 9 2.10. WHEN TREASURY SECURITIES DISREGARDED; DETERMINATION OF HOLDERS’ ACTION 10 2.11. TEMPORARY SECURITIES 10 2.12. CANCELLATION 10 2.13. PAYMENT OF INTEREST; DEFAULTED INTEREST; COMPUTATION OF INTEREST 10 2.14. CUSIP NUMBER 11 2.15. PROVISIONS FOR GLOBAL SECURITIES 11 2.16. PERSONS DEEMED OWNERS 12 ARTICLE 3 REDEMPTION 12 3.1. NOTICES TO TRUSTEE 12 3.2. SELECTION BY TRUSTEE OF SECURITIES TO BE REDEEMED 12
